Daou B, Starke R M, Chalouhi N, Tjoumakaris S, Hasan D, Khoury J, Rosenwasser R H, Jabbour P
From the Department of Neurosurgery (B.D., N.C., S.T., J.K., R.H.R., P.J.), Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania.
Department of Neurological Surgery (R.M.S.), University of Virginia School of Medicine, Charlottesville, Virginia.
AJNR Am J Neuroradiol. 2016 May;37(5):849-55. doi: 10.3174/ajnr.A4613. Epub 2015 Nov 26.
The use of the Pipeline Embolization Device in the management of recurrent previously stented cerebral aneurysms is controversial. The aim of this study was to evaluate the efficacy and safety of the Pipeline Embolization Device in the treatment of recurrent, previously stented aneurysms.
Twenty-one patients with previously stented recurrent aneurysms who later underwent Pipeline Embolization Device placement (group 1) were retrospectively identified and compared with 63 patients who had treatment with the Pipeline Embolization Device with no prior stent placement (group 2). Occlusion at the latest follow-up angiogram, recurrence and retreatment rates, clinical outcome, complications, and morbidity and mortality observed after treatment with the Pipeline Embolization Device were analyzed.
Patient characteristics were similar between the 2 groups. The mean time from stent placement to recurrence was 25 months. Pipeline Embolization Device treatment resulted in complete aneurysm occlusion in 55.6% of patients in group 1 versus 80.4% of patients in group 2 (P = .036). The retreatment rate in group 1 was 11.1% versus 7.1% in group 2 (P = .62). The rate of good clinical outcome at the latest follow-up in group 1 was 81% versus 93.2% in group 2 (P = .1). Complications were observed in 14.3% of patients in group 1 and 9.5% of patients in group 2 (P = .684).
The use of the Pipeline Embolization Device in the management of previously stented aneurysms is less effective than the use of this device in nonstented aneurysms. Prior stent placement can worsen the safety and efficacy profile of this device.
管道栓塞装置用于复发性、先前已植入支架的脑动脉瘤治疗存在争议。本研究旨在评估管道栓塞装置治疗复发性、先前已植入支架的动脉瘤的疗效和安全性。
回顾性纳入21例先前已植入支架的复发性动脉瘤患者,这些患者随后接受了管道栓塞装置置入(第1组),并与63例未预先植入支架而接受管道栓塞装置治疗的患者(第2组)进行比较。分析了在最近一次随访血管造影时的闭塞情况、复发率和再治疗率、临床结局、并发症以及管道栓塞装置治疗后观察到的发病率和死亡率。
两组患者的特征相似。从支架置入到复发的平均时间为25个月。管道栓塞装置治疗使第1组55.6%的患者动脉瘤完全闭塞,而第2组为80.4%(P = 0.036)。第1组的再治疗率为11.1%,第2组为7.1%(P = 0.62)。第1组在最近一次随访时良好临床结局的比例为81%,第2组为93.2%(P = 0.1)。第1组14.3%的患者和第2组9.5%的患者出现并发症(P = 0.684)。
管道栓塞装置用于先前已植入支架的动脉瘤治疗,其效果不如用于未植入支架的动脉瘤。先前植入支架会使该装置的安全性和疗效降低。